January 12, 2022 10:53 AM EST
R&D

As Abec­ma sales take off, Bris­tol My­ers and 2sev­en­ty scrap a fol­low-up CAR-T

Max Gelman

Senior Editor

Bris­tol My­ers Squibb and blue­bird bio spin­out 2sev­en­ty are ax­ing a CAR-T pro­gram in the wake of ris­ing Abec­ma sales. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Biotech VC firm out­lines plans for $100M fund

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times